Bilirubin increases insulin sensitivity by regulating cholesterol metabolism, adipokines and PPAR 3 Levels

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Liu, Jinfeng ^a   Dong, Huansheng ^b   Zhang, Yong ^b,c   Cao, Mingjun ^a   Song, Lili ^a,b   Pan, Qingjie ^a   Bulmer, Andrew ^d   Adams, David B ^b   Dong, Xiao ^c   Wang, Hongjun ^b  

^a Qingdao Institute of Animal Science and Veterinary Medicine   (China)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c QINGDAO AGRICULTURAL UNIVERSITY   (China)

^d GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BILIRUBIN; CHOLESTEROL; GLUCOSE BLOOD LEVEL; INSULIN RECEPTOR; LEPTIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANALYSIS; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; LIVER; MALE; METABOLISM; MOUSE; MOUSE MUTANT; OBESITY;

ADIPOKINES; ADIPONECTIN; ANIMALS; BILIRUBIN; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; LEPTIN; LIPID METABOLISM; LIPIDS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; PPAR GAMMA; RECEPTOR, INSULIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84930628457     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09886     Document Type: Article

References (50)

1. Lee, J. M., Okumura, M. J., Davis, M. M., Herman, W. H. & Gurney, J. G. Prevalence and determinants of insulin resistance among U.S. adolescents: A population-based study. Diabetes Care 29, 2427-2432 (2006).
2. Masuo, K., Rakugi, H., Ogihara, T., Esler, M. D. & Lambert, G. W. Cardiovascular and renal complications of type 2 diabetes in obesity: Role of sympathetic nerve activity and insulin resistance. Curr Diabetes Rev 6, 58-67 (2010).
3. Chu, N. F. et al. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 157, 495-503 (2001).
4. Kahn, B. B. & Flier, J. S. Obesity and insulin resistance. J Clin Invest 106, 473-481 (2000).
5. Li, M. et al. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 57, 1526-1535 (2008).
6. Berg, A. H. & Scherer, P. E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96, 939-949 (2005).
7. Kim, J. Y. et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117, 2621-2637 (2007).
8. Havel, P. J. Control of energy homeostasis and insulin action by adipocyte hormones: Leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 13, 51-59 (2002).
9. Kahn, B. B., Alquier, T., Carling, D. & Hardie, D. G. AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1, 15-25 (2005).
10. Frederich, R. C. et al. Leptin levels reflect body lipid content in mice: Evidence for diet-induced resistance to leptin action. Nat Med 1, 1311-1314 (1995).
11. Berg, A. H., Combs, T. P., Du, X., Brownlee, M. & Scherer, P. E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7, 947-953 (2001).
12. Basu, R., Pajvani, U. B., Rizza, R. A. & Scherer, P. E. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: Differential regulation from nondiabetic subjects. Diabetes 56, 2174-2177 (2007).
13. Maeda, N. et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8, 731-737 (2002).
14. Ouchi, N. et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMPdependent pathway. Circulation 102, 1296-1301 (2000).
15. Gan, S. K. et al. Changes in aerobic capacity and visceral fat but not myocyte lipid levels predict increased insulin action after exercise in overweight and obese men. Diabetes Care 26, 1706-1713 (2003).
16. Kim, D. H. et al. Heme oxygenase-mediated increases in adiponectin decrease fat content and inflammatory cytokines tumor necrosis factor-alpha and interleukin-6 in Zucker rats and reduce adipogenesis in human mesenchymal stem cells. J Pharmacol Exp Ther 325, 833-840 (2008).
17. Choi, J. H. et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466, 451-456 (2010).
18. Iwaki, M. et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52, 1655-1663 (2003).
19. Otterbein, L. E., Soares, M. P., Yamashita, K. & Bach, F. H. Heme oxygenase-1: Unleashing the protective properties of heme. Trends Immunol 24, 449-455 (2003).
20. Ndisang, J. F., Lane, N. & Jadhav, A. The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulin-sensitizing pathways. Endocrinology 150, 2098-2108 (2009).
21. Chen, Y. H. et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 111, 1-8 (2002).
22. Bruce, C. R., Carey, A. L., Hawley, J. A. & Febbraio, M. A. Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes: Evidence that insulin resistance is associated with a disturbed antioxidant defense mechanism. Diabetes 52, 2338-2345 (2003).
23. Arredondo, M., Jorquera, D., Carrasco, E., Albala, C. & Hertrampf, E. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with iron status in persons with type 2 diabetes mellitus. Am J Clin Nutr 86, 1347-1353 (2007).
24. Shakeri-Manesch, S. et al. Diminished upregulation of visceral adipose heme oxygenase-1 correlates with waist-to-hip ratio and insulin resistance. Int J Obes (Lond) 33, 1257-1264 (2009).
25. Li, M. et al. Interdiction of the diabetic state in NOD mice by sustained induction of heme oxygenase: Possible role of carbon monoxide and bilirubin. Antioxid Redox Signal 9, 855-863 (2007).
26. Nicolai, A. et al. Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity-induced diabetic rats. Hypertension 53, 508-515 (2009).
27. Peterson, S. J., Frishman, W. H. & Abraham, N. G. Targeting heme oxygenase: Therapeutic implications for diseases of the cardiovascular system. Cardiol Rev 17, 99-111 (2009).
28. Dong, H. et al. Bilirubin increases insulin sensitivity in leptin-receptor deficient and diet-induced obese mice through suppression of ER stress and chronic inflammation. Endocrinology 155, 818-828 (2014).
29. Stocker, R. Antioxidant activities of bile pigments. Antioxid Redox Signal 6, 841-849 (2004).
30. Schwertner, H. A., Jackson, W. G. & Tolan, G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 40, 18-23 (1994).
31. Wallner, M. et al. Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome. Clin Sci (Lond) 125, 257-264 (2013).
32. Lin, J. P., Vitek, L. & Schwertner, H. A. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 56, 1535-1543 (2010).
33. Breimer, L. H., Wannamethee, G., Ebrahim, S. & Shaper, A. G. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 41, 1504-1508 (1995).
34. Bulmer, A. C., Verkade, H. J. & Wagner, K. H. Bilirubin and beyond: A review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection. Prog Lipid Res 52, 193-205 (2013).
35. Dong, H. et al. Bilirubin Increases Insulin Sensitivity in Leptin-Receptor Deficient and Diet-Induced Obese Mice Through Suppression of ER Stress and Chronic Inflammation. Endocrinology, en20131667 (2014).
36. Wang, H. et al. Bilirubin can induce tolerance to islet allografts. Endocrinology 147, 762-768 (2006).
37. Bulmer, A. C., Blanchfield, J. T., Toth, I., Fassett, R. G. & Coombes, J. S. Improved resistance to serum oxidation in Gilbert's syndrome: A mechanism for cardiovascular protection. Atherosclerosis 199, 390-396 (2008).
38. Tapan, S. et al. Decreased small dense LDL levels in Gilbert's syndrome. Clin Biochem 44, 300-303 (2011).
39. Boon, A. C. et al. Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome. Free Radic Biol Med 52, 2120-2127 (2012).
40. Taub, R. Liver regeneration: From myth to mechanism. Nat Rev Mol Cell Biol 5, 836-847 (2004).
41. Wallner, M. et al. Haem catabolism: A novel modulator of inflammation in Gilbert's syndrome. Eur J Clin Invest 43, 912-919 (2013).
42. Inoue, M. et al. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun 336, 215-222 (2005).
43. Karmakar, S. et al. Black tea prevents high fat diet-induced non-alcoholic steatohepatitis. Phytother Res 25, 1073-1081 (2011).
44. Sindhu, E. R., Firdous, A. P., Preethi, K. C. & Kuttan, R. Carotenoid lutein protects rats from paracetamol-, carbon tetrachlorideand ethanol-induced hepatic damage. J Pharm Pharmacol 62, 1054-1060 (2010).
45. Kapitulnik, J. & Ostrow, J. D. Stimulation of bilirubin catabolism in jaundiced Gunn rats by an induced of microsomal mixedfunction monooxygenases. Proc Natl Acad Sci U S A 75, 682-685 (1978).
46. De Matteis, F., Trenti, T., Gibbs, A. H. & Greig, J. B. Inducible bilirubin-degrading system in the microsomal fraction of rat liver. Mol Pharmacol 35, 831-838 (1989).
47. De Matteis, F., Dawson, S. J., Boobis, A. R. & Comoglio, A. Inducible bilirubin-degrading system of rat liver microsomes: Role of cytochrome P450IA1. Mol Pharmacol 40, 686-691 (1991).
48. Sinal, C. J. & Bend, J. R. Aryl hydrocarbon receptor-dependent induction of cyp1a1 by bilirubin in mouse hepatoma hepa 1c1c7 cells. Mol Pharmacol 52, 590-599 (1997).
49. McCarty, M. F. Serum bilirubin may serve as a marker for increased heme oxygenase activity and inducibility in tissues-A rationale for the versatile health protection associated with elevated plasma bilirubin. Med Hypotheses 81, 607-610 (2013).
50. Wang, H. et al. Donor treatment with carbon monoxide can yield islet allograft survival and tolerance. Diabetes 54, 1400-1406 (2005).